BB Biotech Aktie 3838999 / CH0038389992
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
24.04.2026 07:00:15
|
EQS-Adhoc: BB Biotech AG publishes its interim report
|
EQS-Ad-hoc: BB Biotech AG / Key word(s): Results / Quarter Ad hoc announcement pursuant to Art. 53 LR April 24, 2026 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2026, which covers the results of its business activities for the first three months of 2026. Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2026, amounted to CHF 21 mn (loss of CHF 241 mn in the same period 2025). For an investment company, the results reflect the share price development of the companies held in the portfolio. The interim report as at March 31, 2026, is available under www.bbbiotech.com.
For further information:
Company profile BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research. End of Inside Information
24-Apr-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Milan, SIX |
| EQS News ID: | 2313686 |
| End of Announcement | EQS News Service |
|
|
2313686 24-Apr-2026 CET/CEST
Nachrichten zu BB Biotech AG
Sind wir noch in einem Bullenmarkt?
In diesem Interview sprechen wir mit Börsenprofi Lars über die aktuelle Marktlage. Trotz geopolitischer Krisen und hoher Volatilität zeigen sich die Märkte erstaunlich robust – doch wie lange noch?
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| BB Biotech AG | 44.95 | -2.49% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Anhaltende Rekordlaune an den US-Börsen -- SMI geht tiefer ins Wochenende -- DAX beendet Handelswoche knapp im Minus -- Asiens Börsen letztlich uneinheitlichDer heimische Aktienmarkt notierte im Freitagshandel leichter, während sich der deutsche Leitindex letztlich seitwärts bewegte. Die Wall Street zeigt sich mit verschiedenen Vorzeichen. Die Börsen in Fernost fanden am Freitag keine gemeinsame Richtung.